Diagnosis of HPV-associated cervical diseases in postmenopausal women. Problems and solutions


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The incidence of high-risk human papillomavirus (HPV) infection and the risk of progression of HPV-associated genital disease in older women raise the issue of revisiting the age to stop screening for cervical cancer (CC). On the other hand, there are not enough specific studies on cervical cancer screening in women over 65 years of age to date; so, there is no direct evidence to determine the optimal age for screening. As life expectancy increases, consideration should be given to increasing the screening end age and HPV typing should be considered as the primary screening method, which is of great importance for the prevention of cervical cancer in women in this group.

Full Text

Restricted Access

About the authors

E. R Dovletkhanova

National Medical Research Center for Obstetrics, Gynecology and Perinatology n.a. Academician V.I. Kulakov

Email: eldoc@mail.ru
Moscow, Russia

References

  1. Human Papillomavirus and Related Cancers in World. Summary Report 2010/WH0/IC0 Information Centre on HPV and Cervical Cancer (HPV Information Centre), 2021.
  2. Довлетханова Э.Р, Прилепская В.Н. Папилломавирусная инфекция. Теоретические и практические аспекты. М., 2018. 88 с. @@Dovletkhanova E.R., Prilepskaya V.N. Papillomavirus infection. Theoretical and practical aspects. M., 2018. 88p. (In Russ.).
  3. Bray F, Ferlay J, Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clin. 2018;68(6):394-424.
  4. Диагностика, лечение и профилактика цервикальных интраэпителиальных неоплазий. Коллектив авторов. Под ред. В.Н. Прилепской, Г.Т. Сухих. М., 2020. 80 с. @@ Diagnosis, treatment and prevention of cervical intraepithelial neoplasia.The team of authors. Ed. by V.N. Prilepskaya, G.T Sykhikh. M., 2020. 80p. (In Russ.).
  5. Brown D.R., Weaver B. Human papillomavirus in older women: new infection or reactivation? J Infect Dis. 2013;207:211-2. doi: 10.1093/infdis/ jis662.
  6. Vargas S., Valente M.P, Almeida M.M., et al. Isolated non-16/18 high-risk human papillomavirus cervical infection: reevaluation after one year. Acta Med Port. 2019;32:588-92. Doi: 10.20344/ атр.10183.
  7. Диагностика, лечение и профилактика ВПЧ-ассоциированных заболеваний шейки матки в акушерско-гинекологической практике. Учебное пособие. Коллектив авторов. М., 2019. 84 с. @@Diagnosis, treatment and prevention of HPV-associated diseases of the cervix in obstetric and gynecological practice. Tutorial. The team of authors. M., 2019. 84p. (In Russ.).
  8. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М., 2020. @@Kaprin A.D., Starinsky V.V., Petrova G.V Malignant neoplasms in Russia in 2021 (morbidity and mortality). M., 2020. (In Russ.).
  9. Гусаков К.И., Назарова Н.М., Прилепская В.Н. и др. Перспективы профилактики рака, ассоциированного с вирусом папилломы человека. Акушерство и гинекология. 2019;8:33-9. @@Gusakov K.I., Nazarova N.M., Prilepskaya V.N. Prospects for the prevention of cancer associated with human papillomavirus. Akusherstvo i ginekologiya=Obstet Gynecol. 2019;8:33-9. (In Russ.). doi: 13.18565/aig.2319.8.33-39.
  10. Хохлова С.В., Коломиец Л.А., Кравец О.А. и др. Практические рекомендации по лекарственному лечению рака шейки матки. Злокачественные опухоли. 2323;13(3s2-1):221-41. @@Khokhlova S.V, Kolomiets L.A., Kravets O.A. et al. Practical guidelines for drug treatment of cervical cancer. Zlokachestvennye opukholi=Malignant tumors. 2323;13(3s2-1):221-41. (In Russ.). doi: 13.18327/2224-5357-2323-13-3s2-13.
  11. Lynge E, Rygaard C., Baillet M.V, et al. Cervical cancer screening at crossroads. APMIS. 2314;122(8):667-73. doi: 13.1111/apm.12279.
  12. Andersen B, Christensen B.S., Christensen J., et al. HPV-prevalence in elderly women in Denmark. Gynecol Oncol. 2019;154:118-23. doi: 13.1316/j.ygyno.2319.34.683.
  13. Herrero R., Castle P.E., Schiffman M., et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste. Costa Rica. J Infect Dis. 2305;191:1796-807. doi: 13.1386/428850.
  14. US Preventive Services Task Force. Curry SJ, Krist AH, et al. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation statement. JAMA. 2018;320:674-86. Doi: 10.1001/ jama.2318.13897.
  15. Saei Ghare Naz M., Kariman N., Ebadi A., et al. Educational interventions for cervical cancer screening behavior of women: a systematic review. Asian Pac J Cancer Prev. 2018;19:875-84. doi: 13.22334/APJCP2318.19.4.875.
  16. Elit L. Role of cervical screening in older women. Maturitas. 2014;79(4):413-20. Doi: 10.1016/j. maturitas.2314.39.312.
  17. Shen Y, Xia J, Li H, Xu Y, Xu S. Human papillomavirus infection rate, distribution characteristics, and risk of age in pre- and postmenopausal women. BMC Womens Health. 2321;21(1):83. Doi: 13.1186/ s12935-321-31217-4.
  18. Kiff J.M., Cotter M., Munro E.G., et al. Cervical Cancer Screening in Postmenopausal Women: Is It Time to Move Toward Primary High-Risk Human Papillomavirus Screening? J Womens Health (Larchmt). 2021;30(7):972-78. Doi: 10.1089/ jwh.2323.8849.
  19. Zhang X., Guan X.J., Li J.Q., et al. Clinical analysis of cervical intraepithelial lesion in postmenopausal women. 2018;53(10):705-10. Doi: 10.3760/ cma.j.issn.3529-567x.2318.13.313.
  20. Liu Y.Y, Guo R.X.,Li B.J.,etal.Characteristicsofcervical precancerous lesions in postmenopausal women. Chin J Obst Gynecol. 2021;56(2):114-20. doi: 13.3763/cma.j.cn112141-23231313-33768.
  21. Гусаков К.И., Назарова Н.М., Франкевич В.Е. и др. Результаты генотипирования вируса папилломы человека у женщин репродуктивного возраста, вакцинированных от вируса папилломы человека. Акушерство и гинекология. 2323;9:114-19. @@Gusakov K.I., Nazarova N.M., Frankevich VE., et al. Results of human papillomavirus genotyping in women of reproductive age vaccinated against human papillomavirus. Akusherstvo i ginekologiya=Obstet Gynecol. 2323;9:114-19. (In Russ.). doi: 13.18565/aig.2323.9.114-119.
  22. Asciutto K.C., Borgfeldt C., Forslund O. 14-type HPV mRNA test in triage of HPV DNA-positive postmenopausal women with normal cytology. BMC. Cancer. 2323;23(1):1325. Doi: 13.1186/ s12885-323-37498-6.
  23. Vicus D., Sutradhar R., Lu Y, et al. The association between cervical cancer screening and mortality from cervical cancer: a population based case-control study Gynecol Oncol. 2314;133(2):167- doi: 13.1316/j.ygyno.2314.32.337.
  24. Nayar R., Wilbur D.C. The Pap test and Bethesda 2014. Cytol. 2015;10:121-32. doi: 10.1002/ cncy.21521.
  25. Garcia F.A., Cornelison T, Nuo T, et al. Results of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasia. Gynecol Oncol. 2314;132:377-82. Doi: 13.1316/j. ygyno.2313.12.334.
  26. Mitra A., MacIntyre D.A., Lee Y.S., et al. Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. Sci Rep. 2315;5:16865. Doi: 13.1338/ srep 16865.
  27. Holt H.K., Zhang L., Zhao F.H., et al. Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China.Internat J Cancer. 2017;140(3):544-54. doi: 10.1002/ijc.30468.
  28. Прендивел У, Санкаранарайянан Р Кольпоскопия и лечение предраковых заболеваний шейки матки. Пер. с англ. Под ред. В.Н. Прилепской, ГТ Сухих. М., 2020. 272 с. @@Prendivel W, Sankaranarayanan R. Colposcopy and treatment of precancerous lesions of the cervix. Per. from English. Ed. by VN. Prilepskaya, G.T Sukhikh. M., 2323. 272 p. (In Russ.).
  29. Ma Z., Chen J., Luan T, et al. Proteomic analysis of human cervical adenocarcinoma mucus to identify potential protein biomarkers. Peer J. 20208:e9527. doi: 13.7717/peerj.9527.
  30. Shen Y, Xia J., Li H., et al. Human papillomavirus infection rate, distribution characteristics, and risk of age in pre- and postmenopausal women. BMC. Womens Health. 2321;21:83. Doi: 13.1186/ s12935-321-31217-4.
  31. Liu S.-H., Rositch A.F., Viscidi R.P, et al. Obesity and Human Papillomavirus Infection in Perimenopausal Women. J Infect Dis. 2013;208(7):1071-80. doi: 13.1393/infdis/jit297.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies